Page last updated: 2024-12-11
l 732531
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
32-O-(1-hydroxyethylindol-5-yl)ascomycin: a tacrolimus-related immunosuppressant with reduced toxicity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9876331 |
| MeSH ID | M0285738 |
Synonyms (10)
| Synonym |
|---|
| l-732531 |
| 7VM80M10N6 , |
| 32-o-(1-hydroxyethylindol-5-yl)ascomycin |
| 148365-48-4 |
| indolyl-ascomycin |
| l-732,531 |
| l 732531 |
| unii-7vm80m10n6 |
| (1r,9s,12s,13r,14s,17r,18z,21s,23s,24r,25s,27r)-17-ethyl-1,14-dihydroxy-12-[(1e)-1-[(1r,3r,4r)-4-{[1-(2-hydroxyethyl)-1h-indol-5-yl]oxy}-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]o |
| Q27268916 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The clinical usefulness of tacrolimus is limited, however, by severe adverse effects, including neurotoxicity and nephrotoxicity." | ( A tacrolimus-related immunosuppressant with reduced toxicity. Barker, J; DaSilva, C; Dumont, FJ; Koo, G; Koprak, S; Parsons, WH; Pivnichny, J; Sigal, NH; Sinclair, PJ; Singer, I; Staruch, MJ; Talento, A; Williamson, AR; Wong, F; Woods, J; Wyvratt, M, 1998) | 0.3 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively." | ( Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. Carey, KD; Chiu, SH; Colletti, A; Hawkins, T; Karanam, BV; Lavin, M; Miller, RR; Montgomery, T; Stearns, RA; Tang, YS; Vincent, SH, 1998) | 0.3 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "2 mg/kg to 30 ml/min/kg when dosed at 1 and 3 mg/kg." | ( Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. Carey, KD; Chiu, SH; Colletti, A; Hawkins, T; Karanam, BV; Lavin, M; Miller, RR; Montgomery, T; Stearns, RA; Tang, YS; Vincent, SH, 1998) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||